10 completed, 3 active not recruiting, 1 withdrawn. 14 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 10, Active not recruiting 3, Withdrawn 1 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Acalabrutinib, Duvelisib - Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 1 | Withdrawn | Narendranath Epperla | 2022-07-01 | 2022-06-07 | |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 38 | 2021-10-21 | 2026-07-31 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Duvelisib, Nivolumab - Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | David Bond, MD | 7 | 2019-11-05 | 2024-05-02 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Duvelisib, Venetoclax - Chronic Lymphocytic Leukemia, Richter Syndrome | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 55 | 2018-07-12 | 2026-03-23 |
| Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas Romidepsin, Bortezomib, duvelisib - Lymphoma, Relapsed/Refractory T-cell Lymphomas | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 114 | 2016-05-23 | 2026-04-24 |
| Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma duvelisib - Lymphoma | Phase 1 | Completed | AbbVie | 7 | 2015-11-01 | 2017-02-06 |
| Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 IPI-145 (duvelisib), IPI-145 - Healthy | Phase 1 | Completed | SecuraBio | 103 | 2014-11-01 | 2021-03-17 |
| A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL IPI-145, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 32 | 2014-06-27 | 2026-10-22 |
| Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects IPI-145 - Hepatic Impairment | Phase 1 | Completed | SecuraBio | 24 | 2014-03-01 | 2021-03-17 |
| Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 IPI-145, Rifampin - Healthy | Phase 1 | Completed | SecuraBio | 14 | 2013-10-01 | 2021-03-17 |
| Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam IPI-145, Midazolam - Healthy | Phase 1 | Completed | SecuraBio | 14 | 2013-08-01 | 2021-03-17 |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies IPI-145, Rituximab, Bendamustine - Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | SCRI Development Innovations, LLC | 48 | 2013-05-01 | 2016-07-11 |
| IPI-145 ADME and Absolute Bioavailability Study IPI-145 - Healthy | Phase 1 | Completed | SecuraBio | 6 | 2013-03-01 | 2021-03-17 |
| IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study IPI-145, Placebo - Healthy Volunteers | Phase 1 | Completed | SecuraBio | 106 | 2011-08-01 | 2021-03-17 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (3) · Lymphoma, T-Cell (2) · Hematologic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Mycosis Fungoides (1) · Recurrence (1) · Sezary Syndrome (1)
SecuraBio (6) · Dana-Farber Cancer Institute (2) · AbbVie (1) · David Bond, MD (1) · Memorial Sloan Kettering Cancer Center (1) · Narendranath Epperla (1) · National Cancer Institute (NCI) (1) · SCRI Development Innovations, LLC (1)
United States (10) · Netherlands (2) · Japan (1)
Hagop Youssoufian, MD (6) · David Bond, MD (1) · Ian Flinn, M.D. (1) · Matthew Davids, MD (1) · Matthew S Davids, MD (1) · Narendranath Epperla, MD (1) · Neha Mehta-Shah (1) · Steven Horwitz, MD (1)
PMID 33786583, PMID 38886623, PMID 41886642
UM1CA186689 (1)